Impact of Semaglutide on Tobacco Use and Related Health Behaviors
- Registration Number
- NCT06986993
- Lead Sponsor
- University of Oklahoma
- Brief Summary
This pilot randomized trial will assess the impact of 12 weeks of semaglutide administration (vs placebo) on changes in: (i) tobacco use and related factors (nicotine craving, withdrawal, motivation to quit, etc.) and (ii) biological biomarkers of health (e.g., epigenetics, glucose variability via continuous glucose monitoring \[CGM\], etc.) in adult smokers with obesity (n = 40). We will integrate molecular biology procedures (e.g., epigenetics) to maximize internal validity with real-world smartphone-based ecological momentary assessment (EMA) surveys to maximize external validity
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 40
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Semaglutide Semaglutide Participants will be randomized to receive active semaglutide or placebo (saline) injection once a week for 12weeks Placebo Placebo Participants will be randomized to receive active semaglutide or placebo (saline) injection once a week for 12weeks
- Primary Outcome Measures
Name Time Method Cigarette smoking 12 weeks Changes in number of cigarettes smoked per day
- Secondary Outcome Measures
Name Time Method Weight 12 weeks change in weight (in lbs)
Trial Locations
- Locations (1)
Health Promotion Research Center
🇺🇸Oklahoma City, Oklahoma, United States